Status:
RECRUITING
Qatar Cardiometabolic Registry
Lead Sponsor:
Hamad Medical Corporation
Conditions:
Diabetes Mellitus
Cardiovascular Diseases
Eligibility:
All Genders
18+ years
Brief Summary
Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) are closely related. T2DM risk equivalent for CVD and it remains the major cause of death in T2DM. Thus, patients with T2DM and CVD dis...
Detailed Description
Various investigators have shown that type 2 diabetes is associated with out-of-hospital cardiac arrest and mortality due sudden cardiac arrest \[1,2\]. In comparison to non-diabetic patients, those w...
Eligibility Criteria
Inclusion
- Patients with type 2 diabetes mellitus
- Newly diagnosed heart disease, such as ischemic heart disease, heart failure.
Exclusion
- Patients who do not have type 2 diabetes mellitus
- Preexisting heart disease
Key Trial Info
Start Date :
September 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
50000 Patients enrolled
Trial Details
Trial ID
NCT03394313
Start Date
September 15 2017
End Date
December 31 2027
Last Update
January 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamad Medical Coorporation
Doha, Qatar, 3050